SEC Form 4 · accession 0001193125-26-395837
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roberto Wandenkolk Vieira
Officer — President, Oncology
Period of report
Sep 16, 2026
Accepted (ET)
Sep 18, 2026 · 7:53 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 16, 2026 | S | 296 | $100.82 | D | 3,946 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
- F2Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Remarks
The power of attorney under which this form was signed is on file with the Commission.